Skip to Content
MilliporeSigma
  • Dehydroepiandrosterone sulfate, a useful endogenous probe for evaluation of drug-drug interaction on hepatic organic anion transporting polypeptide (OATP) in cynomolgus monkeys.

Dehydroepiandrosterone sulfate, a useful endogenous probe for evaluation of drug-drug interaction on hepatic organic anion transporting polypeptide (OATP) in cynomolgus monkeys.

Drug metabolism and pharmacokinetics (2015-05-21)
Masaki Watanabe, Takao Watanabe, Masashi Yabuki, Ikumi Tamai
ABSTRACT

Since drug-drug interaction (DDI) can affect organic anion-transporting polypeptide (OATP) and cause clinical events, prediction of such DDI is important in early clinical development. Although statins are useful probes for OATP-mediated DDI, endogenous probes would be more practical for predicting such DDI. In this study, we investigate the possible use of dehydroepiandrosterone sulfate (DHEAS), an endogenous OATP substrate, in predicting OATP-mediated DDI in cynomolgus monkeys as a first step toward in human assessment. In in vitro experiments, both human and cynomolgus monkey hepatocytes showed a time- and temperature-dependent DHEAS uptake. Rifampicin (RIF), a typical OATP inhibitor, inhibited this uptake, indicating the involvement of OATP in DHEAS uptake. In in vivo experiments, the area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) of DHEAS were significantly increased following administration of RIF 10 mg/kg, although the extent of this increase was lower than that observed with the test-statins used in this study. However, based on the results of in vitro hepatic DHEAS uptake, changes in DHEAS concentration are expected to be more prominent in human than in monkey. This shows for the first time that DHEAS may be used as endogenous probe for predicting OATP-mediated DDI.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hydrogen chloride solution, 3 M in cyclopentyl methyl ether (CPME)
Fluvastatin sodium, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium sulfate, JIS special grade, ≥99.0%
Sigma-Aldrich
Hydrogen chloride – ethanol solution, 0.1 M in ethanol
Sigma-Aldrich
Hydrochloric acid solution, 12 M
Sigma-Aldrich
Hydrochloric acid solution, 0.01 M
Sigma-Aldrich
Hydrochloric acid solution, 1 M
Sigma-Aldrich
Hydrochloric acid solution, 0.5 M
Sigma-Aldrich
Hydrochloric acid solution, 6 M
Sigma-Aldrich
Hydrochloric acid solution, 0.05 M
Sigma-Aldrich
Hydrochloric acid solution, 2 M
Sigma-Aldrich
Hydrochloric acid, SAJ first grade, 35.0-37.0%
Sigma-Aldrich
Hydrochloric acid solution, 0.02 M
Sigma-Aldrich
Hydrochloric acid solution, 32 wt. % in H2O, FCC
Sigma-Aldrich
Hydrogen chloride solution, 2.0 M in diethyl ether
Sigma-Aldrich
Sodium sulfate, ACS reagent, ≥99.0%, anhydrous, granular
Sigma-Aldrich
Hydrogen chloride solution, 4.0 M in dioxane
Sigma-Aldrich
Hydrochloric acid, 37 wt. % in H2O, 99.999% trace metals basis
Sigma-Aldrich
Hydrogen chloride solution, 1.0 M in diethyl ether
Sigma-Aldrich
Hydrogen chloride solution, 1.0 M in acetic acid
Sigma-Aldrich
Sodium sulfate, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Hydrochloric acid, ACS reagent, 37%
Sigma-Aldrich
Hydrochloric acid, meets analytical specification of Ph. Eur., BP, NF, fuming, 36.5-38%
Sigma-Aldrich
Hydrochloric acid, puriss., 24.5-26.0%
Sigma-Aldrich
Sodium sulfate, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Sigma-Aldrich
Sodium sulfate, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99%
Sigma-Aldrich
Hydrochloric acid, ACS reagent, 37%
Sigma-Aldrich
Hydrochloric acid, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., fuming, ≥37%, APHA: ≤10
USP
Fluvastatin sodium, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Sodium sulfate, ACS reagent, ≥99.0%, anhydrous, powder